Please assess the completion status of the following clinical trial:

Trial Title: Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥18 years)~* Male of female gender~* In case of non-menopausal women, unwillingness to become pregnant during the study period. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study.~* Written informed consent provided by the patients or by a first-degree relative in case of patients unable to consent~* Presence of at least two signs of SIRS (see below for definition)~* SOFA score ≥2 (see Appendix I)~* PCT ≥0.25 ng/ml~* Presence of at least two of the following signs: i) cough; ii) purulent sputum expectoration; iii) dyspnea; and/or iv) pleuritic chest pain~* Presence of CAP (see below for definition)~SIRS is defined by the presence of at least two of the following criteria:~* Core temperature \>38 Celsius degrees or \<36 Celsius degrees~* Heart rate \>90 beats/minute~* Breath rate \>20 breaths/minute or pco2\<32 mmHg~* Total white blood cell count \>12,000/mm3 or \<4,000/mm3 or \>15% bands~CAP is defined as the presence of auscultatory findings compatible with CAP and new consolidation in chest X-ray in a patient without any history of contact with the hospital environment or with health-care facilities the last 90 days.~Exclusion Criteria:~* Age below 18 years~* Denial of written informed consent~* Presence of infection by SARS-CoV-2 (COVID-19)~* Intake of any macrolide for the current episode of CAP under study~* Oral or intravenous intake of corticosteroids defined as any more than 0.4mg/kg daily intake of equivalent prednisone for the last 15 days~* Neutropenia defined as an absolute neutrophil count below 1,000/mm3~* Known infection by the human immunodeficiency virus~* Any chronic anti-cytokine treatment (e.g. antibodies against TNF for rheumatoid arthritis)~* Hospitalization for more than 2 days the last 90 days~* QTc interval at rest ECG ≥500 msec or history of known congenital long QT syndrome~* Concomitant administration with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4, (lovastatin or simvastatin), and presence of any contraindications for the study drug~* Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): These patients will be treated with 1 placebo tablet every 12 hours and intravenously with ceftriaxone or one β-lactam/β-lactamase combination as part of standard of care therapy indicated by the summary of product characteristics and according to bibliographic references. The total duration of treatment will be seven days.The dose regimen of ceftriaxone will be 2g once daily. The β-lactam/β-lactamase combination can be either amoxycilln/clavulanate or ampicillin/sulbactam or piperacillin/tazobactam. These may be administered three or four times daily and the dose is adjusted according to renal clearance. In case urinary antigen for Legionella spp is positive and/or Mycoplasma pneumoniae spp is isolated in sputum culture and/or in BioFire Respiratory FilmArray, patients will receive intravenously 400mg of moxifloxacin instead of ceftriaxone as part of standard of care therapy according to bibliographic references.
- Clarithromycin (Type: ACTIVE_COMPARATOR): These patients will be treated with 1 tablet of 500 mg of clarithromycin every 12 hours and intravenously with ceftriaxone or one β-lactam/β-lactamase combination as part of standard of care therapy indicated by the summary of product characteristics and according to bibliographic references. The total duration of treatment will be seven days.The dose regimen of ceftriaxone will be 2g once daily. The β-lactam/β-lactamase combination can be either amoxycilln/clavulanate or ampicillin/sulbactam or piperacillin/tazobactam. These may be administered three or four times daily and the dose is adjusted according to renal clearance. In case urinary antigen for Legionella spp is positive and/or Mycoplasma pneumoniae spp is isolated in sputum culture and/or in BioFire Respiratory FilmArray, patients will receive intravenously 400mg of moxifloxacin instead of ceftriaxone as part of standard of care therapy according to bibliographic references.

Based on this trial design, predict the completion outcome and termination type (if applicable).